Cullinan Therapeutics (CGEM) Non Operating Income (2021 - 2023)

Historic Non Operating Income for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$117000.0.

  • Cullinan Therapeutics' Non Operating Income fell 13926.17% to -$117000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $239000.0, marking a year-over-year increase of 31929.82%. This contributed to the annual value of -$199000.0 for FY2024, which is 18326.36% down from last year.
  • As of Q4 2023, Cullinan Therapeutics' Non Operating Income stood at -$117000.0, which was down 13926.17% from $180000.0 recorded in Q3 2023.
  • Over the past 5 years, Cullinan Therapeutics' Non Operating Income peaked at $298000.0 during Q4 2022, and registered a low of -$241000.0 during Q2 2022.
  • Over the past 3 years, Cullinan Therapeutics' median Non Operating Income value was $1000.0 (recorded in 2021), while the average stood at $28800.0.
  • Over the last 5 years, Cullinan Therapeutics' Non Operating Income had its largest YoY gain of 735000.0% in 2022, and its largest YoY loss of 291250.0% in 2022.
  • Cullinan Therapeutics' Non Operating Income (Quarter) stood at $4000.0 in 2021, then skyrocketed by 7350.0% to $298000.0 in 2022, then tumbled by 139.26% to -$117000.0 in 2023.
  • Its Non Operating Income stands at -$117000.0 for Q4 2023, versus $180000.0 for Q3 2023 and $69000.0 for Q2 2023.